Daniel Lawrence Faden, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Papillomavirus Infections | 23 | 2024 | 1615 | 5.770 |
Why?
|
Oropharyngeal Neoplasms | 17 | 2024 | 491 | 5.150 |
Why?
|
Head and Neck Neoplasms | 24 | 2024 | 2896 | 3.970 |
Why?
|
Paranasal Sinus Neoplasms | 4 | 2023 | 242 | 2.130 |
Why?
|
Carcinoma, Squamous Cell | 14 | 2024 | 4021 | 1.900 |
Why?
|
Papillomaviridae | 14 | 2024 | 1120 | 1.830 |
Why?
|
DNA, Viral | 9 | 2024 | 2195 | 1.390 |
Why?
|
Human papillomavirus 16 | 7 | 2024 | 267 | 1.170 |
Why?
|
Alphapapillomavirus | 4 | 2022 | 218 | 1.120 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2024 | 290 | 0.890 |
Why?
|
Genome, Viral | 3 | 2021 | 665 | 0.740 |
Why?
|
Receptors, KIR | 1 | 2019 | 110 | 0.630 |
Why?
|
Nasal Obstruction | 1 | 2021 | 160 | 0.630 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2020 | 170 | 0.630 |
Why?
|
HLA-C Antigens | 1 | 2019 | 141 | 0.630 |
Why?
|
Skull Base | 2 | 2019 | 292 | 0.620 |
Why?
|
Tongue Neoplasms | 2 | 2016 | 183 | 0.580 |
Why?
|
Papillomavirus Vaccines | 1 | 2023 | 496 | 0.560 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 592 | 0.550 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2017 | 74 | 0.550 |
Why?
|
Neurofibroma | 1 | 2017 | 95 | 0.540 |
Why?
|
Levamisole | 1 | 2016 | 35 | 0.530 |
Why?
|
Airway Obstruction | 1 | 2021 | 660 | 0.510 |
Why?
|
Neck | 1 | 2020 | 734 | 0.500 |
Why?
|
Nasal Polyps | 1 | 2021 | 395 | 0.500 |
Why?
|
Aneurysm, False | 1 | 2018 | 255 | 0.500 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 190 | 0.500 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 1051 | 0.490 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2016 | 97 | 0.490 |
Why?
|
DNA, Neoplasm | 4 | 2024 | 1743 | 0.480 |
Why?
|
Point-of-Care Systems | 1 | 2023 | 1213 | 0.470 |
Why?
|
Carotid Arteries | 1 | 2018 | 941 | 0.440 |
Why?
|
Feasibility Studies | 1 | 2024 | 5249 | 0.430 |
Why?
|
Sensory Thresholds | 1 | 2014 | 377 | 0.430 |
Why?
|
Neck Dissection | 1 | 2014 | 201 | 0.420 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2014 | 143 | 0.420 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11118 | 0.410 |
Why?
|
Mutagenesis | 3 | 2021 | 1227 | 0.400 |
Why?
|
Vasculitis | 1 | 2016 | 522 | 0.390 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 561 | 0.390 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2020 | 0.380 |
Why?
|
Mutation | 8 | 2023 | 30006 | 0.370 |
Why?
|
Endoscopy | 2 | 2018 | 1852 | 0.360 |
Why?
|
Neurosurgical Procedures | 2 | 2019 | 2067 | 0.350 |
Why?
|
Electromyography | 1 | 2014 | 1393 | 0.330 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2914 | 0.320 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 4013 | 0.310 |
Why?
|
Humans | 53 | 2024 | 761098 | 0.310 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2813 | 0.310 |
Why?
|
Electric Stimulation Therapy | 1 | 2014 | 625 | 0.310 |
Why?
|
Monitoring, Intraoperative | 1 | 2014 | 943 | 0.300 |
Why?
|
Immunotherapy | 2 | 2024 | 4642 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9278 | 0.290 |
Why?
|
Ultrasonography | 1 | 2020 | 5971 | 0.280 |
Why?
|
Laryngeal Neoplasms | 2 | 2020 | 514 | 0.270 |
Why?
|
Middle Aged | 25 | 2024 | 220835 | 0.260 |
Why?
|
Polymerase Chain Reaction | 2 | 2024 | 6067 | 0.230 |
Why?
|
Toll-Like Receptor 8 | 1 | 2024 | 90 | 0.230 |
Why?
|
Female | 24 | 2024 | 392458 | 0.200 |
Why?
|
Adult | 18 | 2024 | 221083 | 0.200 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 340 | 0.190 |
Why?
|
Prolapse | 1 | 2021 | 63 | 0.190 |
Why?
|
Male | 23 | 2024 | 360675 | 0.190 |
Why?
|
Interferon-gamma | 2 | 2019 | 3155 | 0.180 |
Why?
|
Pharyngeal Neoplasms | 1 | 2020 | 113 | 0.180 |
Why?
|
Aged | 15 | 2024 | 169266 | 0.180 |
Why?
|
In Situ Hybridization | 1 | 2024 | 1900 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2023 | 3634 | 0.170 |
Why?
|
Receptors, KIR3DL2 | 1 | 2019 | 1 | 0.170 |
Why?
|
Multilevel Analysis | 1 | 2019 | 145 | 0.160 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3869 | 0.160 |
Why?
|
Postoperative Period | 1 | 2024 | 1818 | 0.160 |
Why?
|
Glottis | 1 | 2020 | 214 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1008 | 0.160 |
Why?
|
Free Tissue Flaps | 1 | 2023 | 331 | 0.160 |
Why?
|
HLA-A Antigens | 1 | 2019 | 223 | 0.160 |
Why?
|
Laryngectomy | 1 | 2020 | 243 | 0.150 |
Why?
|
Alkaloids | 1 | 2019 | 191 | 0.150 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2019 | 119 | 0.140 |
Why?
|
Triage | 1 | 2024 | 984 | 0.140 |
Why?
|
Aged, 80 and over | 7 | 2024 | 58946 | 0.140 |
Why?
|
Retrospective Studies | 12 | 2024 | 80673 | 0.140 |
Why?
|
Prevalence | 3 | 2024 | 15717 | 0.140 |
Why?
|
Qualitative Research | 2 | 2024 | 3016 | 0.140 |
Why?
|
Propensity Score | 1 | 2024 | 1913 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4739 | 0.130 |
Why?
|
Mouth Neoplasms | 1 | 2020 | 596 | 0.120 |
Why?
|
DNA | 3 | 2023 | 7189 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1220 | 0.120 |
Why?
|
SEER Program | 1 | 2019 | 1450 | 0.120 |
Why?
|
Carcinogens | 1 | 2016 | 452 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 22125 | 0.110 |
Why?
|
Kinetics | 1 | 2022 | 6312 | 0.110 |
Why?
|
Pain, Postoperative | 2 | 2021 | 1738 | 0.110 |
Why?
|
Germ Cells | 1 | 2017 | 632 | 0.110 |
Why?
|
Dendritic Cells | 1 | 2024 | 2726 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12975 | 0.100 |
Why?
|
Epitopes | 1 | 2019 | 2503 | 0.100 |
Why?
|
Angiography | 1 | 2018 | 1597 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4849 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1348 | 0.100 |
Why?
|
Evolution, Molecular | 1 | 2021 | 1882 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 14676 | 0.100 |
Why?
|
Vocal Cords | 1 | 2016 | 520 | 0.090 |
Why?
|
Teaching | 1 | 2019 | 1169 | 0.090 |
Why?
|
Radiosurgery | 1 | 2021 | 1339 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2024 | 3603 | 0.090 |
Why?
|
Vaccination | 1 | 2023 | 3368 | 0.090 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1852 | 0.090 |
Why?
|
Up-Regulation | 1 | 2019 | 4111 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2019 | 2194 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 3197 | 0.080 |
Why?
|
Young Adult | 4 | 2023 | 59199 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 4243 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6781 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39121 | 0.080 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3808 | 0.070 |
Why?
|
Databases, Factual | 2 | 2021 | 7969 | 0.070 |
Why?
|
Contrast Media | 1 | 2020 | 5311 | 0.070 |
Why?
|
ROC Curve | 1 | 2014 | 3582 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2164 | 0.070 |
Why?
|
Antirheumatic Agents | 1 | 2016 | 1366 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2020 | 20600 | 0.060 |
Why?
|
Base Sequence | 1 | 2017 | 12404 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11066 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9416 | 0.060 |
Why?
|
Radiotherapy Dosage | 2 | 2021 | 2898 | 0.050 |
Why?
|
Adolescent | 3 | 2023 | 88271 | 0.050 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16947 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2021 | 64670 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36418 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8529 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15915 | 0.050 |
Why?
|
Incidence | 2 | 2016 | 21357 | 0.050 |
Why?
|
Forearm | 1 | 2023 | 427 | 0.040 |
Why?
|
Radius | 1 | 2023 | 442 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 495 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1089 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 41486 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15308 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 696 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2024 | 2696 | 0.030 |
Why?
|
Prospective Studies | 1 | 2021 | 54419 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12727 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 23415 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29672 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2020 | 1784 | 0.030 |
Why?
|
Nose | 1 | 2019 | 521 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2019 | 637 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2022 | 2913 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 39953 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4565 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3307 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2021 | 12743 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17889 | 0.030 |
Why?
|
Risk Factors | 1 | 2019 | 74219 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3512 | 0.020 |
Why?
|
United States | 1 | 2019 | 72337 | 0.020 |
Why?
|
Smoking | 2 | 2020 | 9055 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4574 | 0.020 |
Why?
|
Metagenome | 1 | 2014 | 447 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3335 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2278 | 0.020 |
Why?
|
Age Distribution | 1 | 2014 | 2873 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5070 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6420 | 0.020 |
Why?
|
Genetic Variation | 1 | 2022 | 6565 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12983 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3591 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2022 | 22157 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18385 | 0.010 |
Why?
|
Clinical Competence | 1 | 2019 | 4786 | 0.010 |
Why?
|
Genomics | 1 | 2014 | 5828 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15634 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81324 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 24013 | 0.010 |
Why?
|
Animals | 1 | 2021 | 168083 | 0.010 |
Why?
|